Texas Roadhouse earnings missed by $0.05, revenue topped estimates
AUSTIN - ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), whose stock has surged over 339% year-to-date according to InvestingPro data, announced Wednesday it has sold its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for $12 million.
The transaction generated $11.7 million in net proceeds on a cash-free, debt-free basis, according to a company press release. The deal represents about 14% of IPA’s current market capitalization of $83.54 million. AVS Bio is a portfolio company of Arlington Capital Partners that provides inputs and services for the bioprocessing and biologics industries.
Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies, said the sale "delivers strong value to IPA and our investors" while allowing the company to focus resources on its AI-based Software as a Service platform.
The biotherapeutics company, which specializes in biologics and drug discovery and currently generates annual revenue of $17.79 million, indicated the proceeds will support investment in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs. InvestingPro analysis suggests the company operates with moderate debt levels and maintains a healthy current ratio of 2.08.
IPA’s operations include biologics discovery, engineering, and characterization, supported by its proprietary LENSai platform powered by HYFT multi-omics technology.
The sale was conducted through a competitive process, with Edgemont Partners serving as exclusive financial advisor to IPA. A 12-month Transition Services Agreement will provide continuity across key functions during the transition period.
IPA stated it holds no material ongoing relationship with AVS Bio or its affiliates beyond the scope of the transaction. For deeper insights into IPA’s financial health and detailed analysis, investors can access comprehensive research reports and additional metrics through InvestingPro, which currently shows 10+ additional investment tips for this stock.
In other recent news, ImmunoPrecise Antibodies Ltd. reported record revenue for the fourth quarter of 2025, achieving $7 million. The company also experienced a notable increase in its gross margin, which rose to 64% from 48% the previous year. These financial results reflect strategic advancements and operational efficiencies within the company. Despite these positive figures, the company’s stock experienced a decline. The adjusted EBITDA loss showed significant improvement, although specific figures were not disclosed in the report. These developments are part of ImmunoPrecise’s ongoing efforts to enhance its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.